Biotechnology & Life Sciences Global On demand · 24-48h

Global Next Generation Sequencing (NGS) Solution Market Strategic Research Report

Global Next Generation Sequencing (NGS) Solution Market Stra…
$3,500 USD
Market Research Reports
Strategic Research Report
Global Next Generation Sequencing (NGS) Solution Market
$5.4B2025
16%CAGR
2032Forecast
Market Research Reports · Global
Market Research Reports Intelligence Series

By Type: Whole Genome Sequencing, Whole Exome Sequencing, Targeted Sequencing and Resequencing Centrifuges

By Application: Sporadic Cancer, Inherited Cancer, Companion Diagnostics, Others

Regional Forecast: Asia Pacific, Latin America, MEA, Europe, North America

Key Players: Eurofins Scientific, Illumina, PerkinElmer, Thermo Fisher Scientific, Roche Holding, Agilent Technologies, Myriad Genetics, Foundation Medicine, Oxford Nanopore Technologies, Pacific Biosciences, Paradigm Diagnostics, BGI Group, Caris Life Sciences, Partek, Natera, LabCorp, Macrogen, Genotypic Technology

Region: Global
Formats: PDF, Excel, Word & PowerPoint
Base year: 2025 · forecast to 2032
Length: 135 pages
Market size 2025
$5.4B
Billion USD
Forecast CAGR
16%
2025-2032
Forecast 2032
$15.3B
Projected
Regiões
5
Asia Pacific · Latin America · MEA · Europe · North America

Visão geral

Scope of the Report

The global Next Generation Sequencing (NGS) Solution market size is predicted to grow from US$ 5,400 million in 2025 to US$ 14,960 million in 2032; it is expected to grow at a CAGR of 16.0% from 2026 to 2032.

Next Generation Sequencing (NGS), also known as high-throughput sequencing, refers to advanced genomic technologies that enable the rapid and cost-effective sequencing of DNA or RNA molecules. NGS solutions have revolutionized the field of genomics and have significant applications in various areas of life sciences, including medical research, diagnostics, personalized medicine, agriculture, and environmental studies.

The global market for Next Generation Sequencing (NGS) solutions has experienced significant growth in recent years, driven by the increasing adoption of NGS technologies in various research and clinical applications. NGS has revolutionized genomics research, personalized medicine, and diagnostics, making it one of the most impactful technologies in the life sciences industry. Continuous innovations in NGS platforms, sequencing chemistries, and bioinformatics tools have improved sequencing accuracy, speed, and data analysis capabilities. The increasing focus on understanding the genetic basis of diseases, population genomics, and agricultural genomics has driven the demand for NGS solutions. The United States and Canada are major contributors to the global NGS market due to their well-established research infrastructure and a large number of NGS-based research projects. European countries, including the United Kingdom, Germany, and France, have seen significant NGS adoption in both research and clinical applications. Countries like China, Japan, and India have witnessed rapid growth in the NGS market, driven by increasing research investments and government initiatives. The global market for NGS solutions is expected to continue its growth trajectory in the coming years. The increasing adoption of NGS in clinical diagnostics, precision medicine, and agriculture is likely to drive further market expansion. Moreover, ongoing advancements in NGS technologies, such as single-cell sequencing and long-read sequencing, will continue to unlock new research possibilities and applications, expanding the reach of NGS into various scientific disciplines.

This report presents a comprehensive overview of the global Next Generation Sequencing (NGS) Solution market, covering market size and forecast, segmentation by product type and application, competitive landscape, leading players and regional and country-level outlook.

Segment by Type

  • Whole Genome Sequencing
  • Whole Exome Sequencing
  • Targeted Sequencing and Resequencing Centrifuges

Segment by Application

  • Sporadic Cancer
  • Inherited Cancer
  • Companion Diagnostics
  • Others

Who Can Use This Report?

This report is written for decision-makers who need a clear, data-backed view of the global Next Generation Sequencing (NGS) Solution market:

  • Manufacturers, suppliers and solution providers benchmarking their position and planning product, capacity and go-to-market strategy
  • Distributors, channel partners and end users in Sporadic Cancer, Inherited Cancer, Companion Diagnostics evaluating demand and sourcing options
  • Investors, financial analysts and consultants assessing growth opportunities, competitive dynamics and M&A potential
  • Government agencies, industry associations and research institutions tracking industry developments and policy impact

Market snapshot

Global Next Generation Sequencing (NGS) Solution Market Strategic Research Report snapshot, 2025–2032

Source: Market Research Reports
Market size CAGR 16%
Regional growth momentum
Market share by segment
Key metrics
Base value
$5.4B
2025
Forecast
$15.3B
2032
CAGR
16%
2025–2032
Regiões
5
global
Key companies
Eurofins ScientificIlluminaPerkinElmerThermo Fisher ScientificRoche HoldingAgilent TechnologiesMyriad GeneticsFoundation Medicine
© MarketResearchReports.comDisclaimer: The actual data may vary in the final report which undergoes verification check post order confirmation.

Segments covered in this report

By Type
Whole Genome SequencingWhole Exome SequencingTargeted Sequencing and Resequencing Centrifuges
By Application
Sporadic CancerInherited CancerCompanion DiagnosticsOthers

Table of contents

Click a chapter to expand
01Executive Summary
02Industry Overview & Forecast
  • 2.1.1 Market Definition and Scope
  • 2.1.2 Market Size and Growth Forecast
  • 2.1.3 Volume Analysis
  • 2.1.4 Segment Outlook by Type
  • 2.1.5 Segment Outlook by Application
  • 2.1.6 Regional Outlook
  • 2.1.7 Structural Developments Shaping the Forecast
  • 2.1.8 Forecast Risks and Sensitivities
03Market Segmentation by Type
  • 3.1 Market Segmentation by Type
  • 3.1.1 Market by Type Overview
  • 3.1.2 Whole Genome Sequencing
  • 3.1.3 Whole Exome Sequencing
  • 3.1.4 Targeted Sequencing and Resequencing Centrifuges
  • 3.1.5 Volume Analysis
04Market Segmentation by Application
  • 4.1 Market Segmentation by Application
  • 4.1.1 Market by Application Overview
  • 4.1.2 Sporadic Cancer
  • 4.1.3 Inherited Cancer
  • 4.1.4 Companion Diagnostics
  • 4.1.5 Others
  • 4.1.6 Volume Analysis
05Regional Market Forecast
  • Asia Pacific
  • North America
  • Europe
  • Middle East & Africa
  • Latin America
06Country-Level Market Forecast
  • 6.1 Asia Pacific
  • 6.1.1 China
  • 6.1.2 Japan
  • 6.1.3 Korea
  • 6.1.4 Southeast Asia
  • 6.1.5 India
  • 6.1.6 Australia
  • 6.1.7 Rest of Asia Pacific
  • 6.2 North America
  • 6.2.1 United States
  • 6.2.2 Canada
  • 6.2.3 Mexico
  • 6.2.4 Rest of North America
  • 6.3 Europe
  • 6.3.1 Germany
  • 6.3.2 France
  • 6.3.3 UK
  • 6.3.4 Italy
  • 6.3.5 Russia
  • 6.3.6 Rest of Europe
  • 6.4 Middle East & Africa
  • 6.4.1 Egypt
  • 6.4.2 South Africa
  • 6.4.3 Israel
  • 6.4.4 Turkey
  • 6.4.5 GCC Countries
  • 6.4.6 Rest of Middle East & Africa
  • 6.5 Latin America
  • 6.5.1 Brazil
  • 6.5.2 Rest of Latin America
07Growth Drivers & Inhibitors
  • 7.1 Growth Drivers & Inhibitors
  • 7.1.1 Section Overview
  • 7.1.2 Growth Drivers
  • 7.1.3 Growth Inhibitors
  • 7.1.4 Driver and Inhibitor Impact Assessment
  • 7.1.5 Analyst Perspective
08Key Company Profiles
  • 8.1 Eurofins Scientific
  • 8.1.1 Company Overview
  • 8.1.2 Key Products & Segments
  • 8.1.3 Financial Performance (2023–2025)
  • 8.1.4 Business Strategy
  • 8.1.5 SWOT Analysis
  • 8.1.6 Strategic Implications (2026–2032)
  • 8.2 Illumina
  • 8.2.1 Company Overview
  • 8.2.2 Key Products & Segments
  • 8.2.3 Financial Performance (2023–2025)
  • 8.2.4 Business Strategy
  • 8.2.5 SWOT Analysis
  • 8.2.6 Strategic Implications (2026–2032)
  • 8.3 PerkinElmer
  • 8.3.1 Company Overview
  • 8.3.2 Key Products & Segments
  • 8.3.3 Financial Performance (2023–2025)
  • 8.3.4 Business Strategy
  • 8.3.5 SWOT Analysis
  • 8.3.6 Strategic Implications (2026–2032)
  • 8.4 Thermo Fisher Scientific
  • 8.4.1 Company Overview
  • 8.4.2 Key Products & Segments
  • 8.4.3 Financial Performance (2023–2025)
  • 8.4.4 Business Strategy
  • 8.4.5 SWOT Analysis
  • 8.4.6 Strategic Implications (2026–2032)
  • 8.5 Roche Holding
  • 8.5.1 Company Overview
  • 8.5.2 Key Products & Segments
  • 8.5.3 Financial Performance (2023–2025)
  • 8.5.4 Business Strategy
  • 8.5.5 SWOT Analysis
  • 8.5.6 Strategic Implications (2026–2032)
  • 8.6 Agilent Technologies
  • 8.6.1 Company Overview
  • 8.6.2 Key Products & Segments
  • 8.6.3 Financial Performance (2023–2025)
  • 8.6.4 Business Strategy
  • 8.6.5 SWOT Analysis
  • 8.6.6 Strategic Implications (2026–2032)
  • 8.7 Myriad Genetics
  • 8.7.1 Company Overview
  • 8.7.2 Key Products & Segments
  • 8.7.3 Financial Performance (2023–2025)
  • 8.7.4 Business Strategy
  • 8.7.5 SWOT Analysis
  • 8.7.6 Strategic Implications (2026–2032)
  • 8.8 Foundation Medicine
  • 8.8.1 Company Overview
  • 8.8.2 Key Products & Segments
  • 8.8.3 Financial Performance (2023–2025)
  • 8.8.4 Business Strategy
  • 8.8.5 SWOT Analysis
  • 8.8.6 Strategic Implications (2026–2032)
  • 8.9 Oxford Nanopore Technologies
  • 8.9.1 Company Overview
  • 8.9.2 Key Products & Segments
  • 8.9.3 Financial Performance (2023–2025)
  • 8.9.4 Business Strategy
  • 8.9.5 SWOT Analysis
  • 8.9.6 Strategic Implications (2026–2032)
  • 8.10 Pacific Biosciences
  • 8.10.1 Company Overview
  • 8.10.2 Key Products & Segments
  • 8.10.3 Financial Performance (2023–2025)
  • 8.10.4 Business Strategy
  • 8.10.5 SWOT Analysis
  • 8.10.6 Strategic Implications (2026–2032)
  • 8.11 Paradigm Diagnostics
  • 8.11.1 Company Overview
  • 8.11.2 Key Products & Segments
  • 8.11.3 Financial Performance (2023–2025)
  • 8.11.4 Business Strategy
  • 8.11.5 SWOT Analysis
  • 8.11.6 Strategic Implications (2026–2032)
  • 8.12 BGI Group
  • 8.12.1 Company Overview
  • 8.12.2 Key Products & Segments
  • 8.12.3 Financial Performance (2023–2025)
  • 8.12.4 Business Strategy
  • 8.12.5 SWOT Analysis
  • 8.12.6 Strategic Implications (2026–2032)
  • 8.13 Caris Life Sciences
  • 8.13.1 Company Overview
  • 8.13.2 Key Products & Segments
  • 8.13.3 Financial Performance (2023–2025)
  • 8.13.4 Business Strategy
  • 8.13.5 SWOT Analysis
  • 8.13.6 Strategic Implications (2026–2032)
  • 8.14 Partek
  • 8.14.1 Company Overview
  • 8.14.2 Key Products & Segments
  • 8.14.3 Financial Performance (2023–2025)
  • 8.14.4 Business Strategy
  • 8.14.5 SWOT Analysis
  • 8.14.6 Strategic Implications (2026–2032)
  • 8.15 Natera
  • 8.15.1 Company Overview
  • 8.15.2 Key Products & Segments
  • 8.15.3 Financial Performance (2023–2025)
  • 8.15.4 Business Strategy
  • 8.15.5 SWOT Analysis
  • 8.15.6 Strategic Implications (2026–2032)
  • 8.16 LabCorp
  • 8.16.1 Company Overview
  • 8.16.2 Key Products & Segments
  • 8.16.3 Financial Performance (2023–2025)
  • 8.16.4 Business Strategy
  • 8.16.5 SWOT Analysis
  • 8.16.6 Strategic Implications (2026–2032)
  • 8.17 Macrogen
  • 8.17.1 Company Overview
  • 8.17.2 Key Products & Segments
  • 8.17.3 Financial Performance (2023–2025)
  • 8.17.4 Business Strategy
  • 8.17.5 SWOT Analysis
  • 8.17.6 Strategic Implications (2026–2032)
  • 8.18 Genotypic Technology
  • 8.18.1 Company Overview
  • 8.18.2 Key Products & Segments
  • 8.18.3 Financial Performance (2023–2025)
  • 8.18.4 Business Strategy
  • 8.18.5 SWOT Analysis
  • 8.18.6 Strategic Implications (2026–2032)
09Competitive Landscape
  • 9.1 Competitive Landscape Overview
  • 9.2 Competitive Intensity Assessment
  • 9.3 Key Player Strategies & Positioning
  • 9.4 Competitive Dynamics & Strategic Outlook
  • 9.4.1 Emerging Competitive Threats
  • 9.4.2 Consolidation vs. Fragmentation Outlook
  • 9.4.3 Competitive Response Matrix
  • 9.4.4 Strategic Recommendations, 2026–2032
10Porter's Five Forces Analysis
  • 10.1 Threat of New Entrants
  • 10.2 Bargaining Power of Buyers
  • 10.3 Bargaining Power of Suppliers
  • 10.4 Threat of Substitutes
  • 10.5 Competitive Rivalry
11PESTLE Analysis
  • 11.1 Political
  • 11.2 Economic
  • 11.3 Social and Demographic
  • 11.4 Technological
  • 11.5 Legal and Regulatory
  • 11.6 Environmental
  • 11.7 Strategic Implications of the PESTLE Assessment
12SWOT Analysis
13Future Trends & Outlook
  • 13.1 Future Trends & Outlook
  • 13.1.1 Trend Summary and Commercial Maturity Assessment
  • 13.1.2 Technology and Innovation Trends
  • 13.1.3 Long-Term Market Outlook
  • 13.1.4 Investment & M&A Activity Outlook
  • 13.1.5 Overall Outlook Assessment

Frequently asked questions

What is the current global Next Generation Sequencing (NGS) Solution market size?
The global Next Generation Sequencing (NGS) Solution market is estimated at US$ 5.4 billion in 2025 (base year) and is projected to reach US$ 14.96 billion by 2032.
What growth rate is expected for the Next Generation Sequencing (NGS) Solution market through 2032?
The market is expected to grow at a CAGR of 16.0% from 2026 to 2032, expanding from US$ 5.4 billion in 2025 to US$ 14.96 billion in 2032, roughly 2.8 times its base-year value.
How is Next Generation Sequencing (NGS) Solution defined?
Next Generation Sequencing (NGS), also known as high-throughput sequencing, refers to advanced genomic technologies that enable the rapid and cost-effective sequencing of DNA or RNA molecules. NGS solutions have revolutionized the field of genomics and have significant applications in various areas of life sciences, including medical research, diagnostics, personalized medicine, agriculture, and environmental studies.
How is the Next Generation Sequencing (NGS) Solution market segmented by type?
By type, the market is segmented into Whole Genome Sequencing, Whole Exome Sequencing and Targeted Sequencing and Resequencing Centrifuges.
What are the key applications of Next Generation Sequencing (NGS) Solution?
Key applications covered include Sporadic Cancer, Inherited Cancer, Companion Diagnostics and Others.
Which companies are profiled in the Next Generation Sequencing (NGS) Solution market report?
Key players profiled include Eurofins Scientific, Illumina, PerkinElmer, Thermo Fisher Scientific, Roche Holding, Agilent Technologies, Myriad Genetics and Foundation Medicine, among 18 companies covered in total.
What geographies does the Next Generation Sequencing (NGS) Solution market analysis include?
The market is analysed across Asia Pacific, North America, Europe, Middle East & Africa and Latin America, with 20 country-level markets including China, Japan, United States, Canada, Germany, France, Egypt and South Africa.
What are the key demand drivers for Next Generation Sequencing (NGS) Solution?
The global market for Next Generation Sequencing (NGS) solutions has experienced significant growth in recent years, driven by the increasing adoption of NGS technologies in various research and clinical applications.
Who should buy the Next Generation Sequencing (NGS) Solution market report?
The report is intended for manufacturers and solution providers, distributors and end users in Sporadic Cancer, Inherited Cancer and Companion Diagnostics, investors and consultants, and government or industry bodies who need market size, segmentation, competitive and regional data for the Next Generation Sequencing (NGS) Solution market.
What license options are available for this report?
The report is available as a Single User License (US$ 3,500, one named user), a Site License (US$ 5,250, up to 10 users) and a Global / Corporate License (US$ 7,000, unlimited users), all delivered in PDF format.

Research Methodology

All MarketResearchReports.com strategic research reports follow a rigorous, multi-stage methodology combining AI-assisted data synthesis with expert analyst validation.

01
Secondary Research & Data Aggregation

Systematic collection from 500+ verified sources including SEC filings, industry databases (Bloomberg, Statista, OECD), regulatory filings, trade publications, patent databases, and company annual reports. AI-assisted extraction identifies relevant data points across 10,000+ documents per report.

02
Market Sizing — Bottom-Up & Top-Down

Dual-validation approach: bottom-up sizing aggregates segment-level production, consumption, and trade data; top-down sizing cross-validates against macroeconomic indicators and total addressable market estimates. Discrepancies >5% trigger analyst review.

03
Competitive Intelligence

Company profiles built from public financial disclosures, product launches, M&A activity, job postings (as capability proxies), and supply chain mapping. Market share estimates triangulated across revenue, capacity, and shipment data.

04
Demand Forecasting

CAGR projections use time-series regression on 5-10 years of historical data, adjusted for identified demand drivers (technology adoption curves, regulatory catalysts, demographic shifts) and demand inhibitors (cost barriers, substitution risk). Scenario modeling covers base, optimistic, and conservative cases.

05
Analyst Validation & Quality Assurance

All quantitative outputs reviewed by a domain-specialist analyst before publication. Data triangulation requires minimum 3 independent sources for every key figure. Reports undergo a structured peer review against our 47-point quality checklist covering methodology, data citations, logical consistency, and formatting standards.

06
Continuous Updates

On-demand reports are generated at time of purchase, incorporating the most recent available data. Static reports are republished when underlying market conditions shift by >10% from baseline assumptions. Purchasers receive update notifications for 12 months.

Select a license
from US$ 3.500,00
Report License Type
Optional add-ons
On demand · delivered within 24-48 hours
Secure checkout · SSL encrypted
License terms included
Post-purchase analyst support
Custom research

Need a customized version?

Get country-, segment- or company-specific intelligence tailored to your exact requirements.

Request custom research →
Talk to a research advisor USA: +1-302-703-9904 India: +91-8762746600
Trusted by

Leading Brands in This Industry

Logos are trademarks of their respective owners and indicate a verified past business relationship, not a current partnership or endorsement.